pd 98059 has been researched along with gemcitabine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fry, DW; Nelson, JM | 1 |
| Batra, SK; Davis, JS; Davis, TL; Hauke, R; Lin, FF; Lin, MF; Schutte, R; Zelivianski, S; Zhang, L | 1 |
| Jiang, Y; Liu, F; Sun, S; Tang, Y; Zheng, C | 1 |
| Chiu, CC; Hour, TC; Hsu, SH; Hsu, WC; Hu, HT; Huang, AM; Kao, YT; Lin, CS; Lu, CY; Pu, YS | 1 |
| Chen, L; Chen, M; Dai, F; He, M; Pan, T; Shen, P; Song, Y; Wan, X; Wang, Q; Xiao, P | 1 |
| Aasrum, M; Amrutkar, M; Gladhaug, IP; Verbeke, CS | 1 |
6 other study(ies) available for pd 98059 and gemcitabine
| Article | Year |
|---|---|
Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition.
Topics: Apoptosis; Chromones; Deoxycytidine; Enzyme Inhibitors; Flavonoids; Gemcitabine; Humans; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2001 |
Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gemcitabine; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Time Factors; Tyrphostins | 2009 |
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Clusterin; Deoxycytidine; Flavonoids; Gemcitabine; Gene Knockdown Techniques; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Thionucleotides | 2012 |
Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Flavonoids; Gemcitabine; Humans; Imidazoles; p38 Mitogen-Activated Protein Kinases; Pyridines; Urinary Bladder Neoplasms | 2014 |
Inhibition of ERĪ±/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Autophagy; Beclin-1; Breast Neoplasms; Cytoprotection; Deoxycytidine; Estrogen Receptor alpha; Female; Flavonoids; Gemcitabine; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Prohibitins; RNA Interference; RNA, Small Interfering; Sequestosome-1 Protein; Signal Transduction | 2016 |
Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Coculture Techniques; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Extracellular Matrix; Fibronectins; Flavonoids; Gemcitabine; Humans; MAP Kinase Signaling System; Oligopeptides; Pancreatic Neoplasms; Pancreatic Stellate Cells; Phosphorylation; Proteome; Proto-Oncogene Proteins c-akt | 2019 |